$38.81
00.00%
Pre-Market: 4:52 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Protagonist Therapeutics (NASDAQ:PTGX) Stock, Analyst Ratings, Price Targets, Forecasts
Protagonist Therapeutics Inc has a consensus price target of $46.7 based on the ratings of 11 analysts. The high is $70 issued by JMP Securities on November 15, 2021. The low is $30 issued by SVB Leerink on May 5, 2022. The 3 most-recent analyst ratings were released by JP Morgan, BTIG, and JMP Securities on July 25, 2024, July 24, 2024, and June 17, 2024, respectively. With an average price target of $48 between JP Morgan, BTIG, and JMP Securities, there's an implied 23.68% upside for Protagonist Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
BTIG
JMP Securities
HC Wainwright & Co.
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Protagonist Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/25/2024 | Buy Now | 23.68% | JP Morgan | Brian Cheng | $39 → $48 | Maintains | Overweight | Get Alert |
| 07/24/2024 | Buy Now | 31.41% | BTIG | Julian Harrison | $41 → $51 | Maintains | Buy | Get Alert |
| 06/17/2024 | Buy Now | 15.95% | JMP Securities | Jonathan Wolleben | $45 → $45 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/14/2024 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 15.95% | JMP Securities | Jonathan Wolleben | $42 → $45 | Maintains | Market Outperform | Get Alert |
| 03/11/2024 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | $38 → $38 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 8.22% | JMP Securities | Jonathan Wolleben | → $42 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/28/2024 | Buy Now | -4.66% | JP Morgan | Brian Cheng | $34 → $37 | Maintains | Overweight | Get Alert |
| 02/28/2024 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | -4.66% | JMP Securities | Jonathan Wolleben | $35 → $37 | Maintains | Market Outperform | Get Alert |
| 10/30/2023 | Buy Now | — | Capital One | Tim Chiang | — | Initiates | → Overweight | Get Alert |
| 10/10/2023 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2023 | Buy Now | -12.39% | JP Morgan | Brian Cheng | $36 → $34 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | Buy Now | -9.82% | JMP Securities | Jonathan Wolleben | $28 → $35 | Maintains | Market Outperform | Get Alert |
| 07/03/2023 | Buy Now | -9.82% | Piper Sandler | Yasmeen Rahimi | → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 07/03/2023 | Buy Now | 5.64% | BTIG | Julian Harrison | → $41 | Reiterates | → Buy | Get Alert |
| 06/12/2023 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 04/27/2023 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | -27.85% | JMP Securities | Jonathan Wolleben | $31 → $28 | Maintains | Market Outperform | Get Alert |
| 03/16/2023 | Buy Now | -2.09% | HC Wainwright & Co. | Douglas Tsao | $33 → $38 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | -20.12% | JMP Securities | Jonathan Wolleben | $21 → $31 | Maintains | Market Outperform | Get Alert |
| 11/10/2022 | Buy Now | -14.97% | HC Wainwright & Co. | Douglas Tsao | $50 → $33 | Maintains | Buy | Get Alert |
| 08/25/2022 | Buy Now | -45.89% | JMP Securities | Jonathan Wolleben | → $21 | Reinstates | → Market Outperform | Get Alert |
| 05/18/2022 | Buy Now | -9.82% | Piper Sandler | Yasmeen Rahimi | $60 → $35 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | -22.7% | SVB Leerink | Joseph Schwartz | $50 → $30 | Maintains | Outperform | Get Alert |
| 02/11/2022 | Buy Now | 41.72% | BTIG | Timothy Chiang | → $55 | Initiates | → Buy | Get Alert |
| 11/15/2021 | Buy Now | 80.37% | JMP Securities | Gobind Singh | — | Maintains | Market Outperform | Get Alert |
| 10/13/2021 | Buy Now | 54.6% | JMP Securities | Gobind Singh | — | Maintains | Market Outperform | Get Alert |
| 10/12/2021 | Buy Now | 41.72% | JP Morgan | Anupam Rama | — | Upgrade | Neutral → Overweight | Get Alert |
| 10/12/2021 | Buy Now | 28.83% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
| 10/11/2021 | Buy Now | 3.07% | Northland Capital Markets | Tim Chiang | — | Upgrade | Market Perform → Outperform | Get Alert |
| 09/22/2021 | Buy Now | 21.1% | JMP Securities | Gobind Singh | — | Maintains | Market Outperform | Get Alert |
| 09/20/2021 | Buy Now | 28.83% | HC Wainwright & Co. | Douglas Tsao | — | Maintains | Buy | Get Alert |
| 09/20/2021 | Buy Now | -9.82% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
| 09/20/2021 | Buy Now | 26.26% | JP Morgan | Anupam Rama | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/06/2021 | Buy Now | 54.6% | HC Wainwright & Co. | Douglas Tsao | — | Maintains | Buy | Get Alert |
| 08/05/2021 | Buy Now | 28.83% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ:PTGX) was reported by JP Morgan on July 25, 2024. The analyst firm set a price target for $48.00 expecting PTGX to rise to within 12 months (a possible 23.68% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Protagonist Therapeutics (PTGX)?
The latest analyst rating for Protagonist Therapeutics (NASDAQ:PTGX) was provided by JP Morgan, and Protagonist Therapeutics maintained their overweight rating.
When was the last upgrade for Protagonist Therapeutics (PTGX)?
The last upgrade for Protagonist Therapeutics Inc happened on October 12, 2021 when JP Morgan raised their price target to $55. JP Morgan previously had a neutral for Protagonist Therapeutics Inc.
When was the last downgrade for Protagonist Therapeutics (PTGX)?
The last downgrade for Protagonist Therapeutics Inc happened on September 20, 2021 when JP Morgan changed their price target from N/A to $49 for Protagonist Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Protagonist Therapeutics (PTGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protagonist Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protagonist Therapeutics was filed on July 25, 2024 so you should expect the next rating to be made available sometime around July 25, 2025.
Is the Analyst Rating Protagonist Therapeutics (PTGX) correct?
While ratings are subjective and will change, the latest Protagonist Therapeutics (PTGX) rating was a maintained with a price target of $39.00 to $48.00. The current price Protagonist Therapeutics (PTGX) is trading at is $38.81, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.